TerminatedNCT03422094Updated Oct 27, 2021

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

A Phase 1 interventional study of NeoVax and Nivolumab in Glioblastoma, sponsored by Washington University School of Medicine. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-27.

Sponsored by Washington University School of Medicine · Phase 1, Interventional, and Treatment

Why this study was terminated

Manufacturer changed focus to cell therapy

Phase: Phase 1
Study type: Interventional
Enrollment: 3
Allocation: Non-randomized
Ages: 18 Years and older
Sex: All

Study summary

This is a single institution, open-label, multi-arm, pilot study assessing the safety, feasibility, and immunogenicity of a personalized neoantigen-based vaccine plus poly-ICLC (NeoVax) combined with immune checkpoint inhibitors in subjects with newly diagnosed, unmethylated glioblastoma.

Conditions studied

Glioblastoma

Browse trials for

Glioblastoma 1,917

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No

Inclusion criteria

Newly diagnosed histologically confirmed unmethylated glioblastoma multiforme (WHO grade IV). Patients with secondary glioblastoma, in particular those who are IDH1 or IDH2 mutant, will not be excluded. Unmethylated MGMT must be confirmed by a PCR-based assay.
Patients who had craniotomy with biopsy, subtotal resection, total gross resection, or re-resection will be permitted.
Consented to genome sequencing and dbGaP-based data sharing and has provided or will provide germline (PBMC) and tumor DNA/RNA samples of adequate quality for sequencing. (Acquisition of specimens for sequencing and the sequencing itself may be done as part of routine care or another research project.)
At least 18 years of age.
Karnofsky performance status ≥ 60%
Normal bone marrow and organ function as defined below:
- Absolute neutrophil count ≥ 1,500/mcL
- Platelets ≥ 100,000/mcL
- Total bilirubin ≤ 1.5 x institutional upper limit of normal (IULN)
- AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN
- Creatinine ≤ IULN OR creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
Systemic corticosteroid therapy is permitted provided dosing is no greater than 4 mg per day (dexamethasone or equivalent) on the day of vaccine administration.
Bevacizumab will be allowed if given for symptomatic control of vasogenic edema and to avoid high dose of corticosteroids.
Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation, including at least 5 months (for women of childbearing potential) and at least 7 months (for men) after last dose of study drug. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion criteria

Exclusion Criteria:

As this study aims to assess the immunogenicity of various vaccine plus adjuvant combinations, no prior immunotherapy will be permitted.
Inadequate tissue acquisition to allow for neoantigen screening.
No candidate neoantigen identified during screening.
A history of other malignancy ≤ 3 years previous with the exception of non-melanoma skin cancer, any in situ cancer that has been successfully resected and cured, treated superficial bladder cancer, or any early-stage solid tumor that was successfully resected without need for adjuvant radiation or chemotherapy.
Receiving any other investigational agents within 4 weeks of beginning study treatment.
Known allergy, or history of serious adverse reaction to, vaccines such as anaphylaxis, hives, or respiratory difficulty.
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to poly-ICLC or other agents used in the study.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
History of pre-existing immunodeficiency disorder or autoimmune condition requiring immunosuppressive therapy. This includes inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia, immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, sarcoidosis, or other rheumatologic disease or any other medical condition or use of medication which might make it difficult for the patient to complete the full course of treatments or to generate an immune response to vaccines.
Presence of clinically significant increased intracranial pressure (e.g. impending herniation) or hemorrhage, uncontrolled seizures, or requirement for immediate palliative treatment.
Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 7 days of first dose of vaccine.

Study design

Phase: Phase 1
Primary purpose: Treatment
Allocation: Non-randomized
Intervention model: Sequential assignment
Masking: None (open label)
Enrollment: 3 participants (actual)

Study arms

Experimental
Cohort A: NeoVax+Nivolumab (start at time of progression)
* NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase) * Nivolumab 480 mg i.v. given on Day 1 of each cycle beginning at time of progression
Biological: NeoVax · Biological: Nivolumab · Procedure: Research blood draw · Procedure: Leukapheresis for research
Experimental
Cohort B: NeoVax+Nivolumab (start with Cycle 2)
* NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase) * Nivolumab 480 mg i.v. given on Day 1 of each cycle beginning with Cycle 2 (start of boosting phase)
Biological: NeoVax · Biological: Nivolumab · Procedure: Research blood draw · Procedure: Leukapheresis for research
Experimental
Cohort C: NeoVax + Nivolumab (start with Cycle 1)
* NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase) * Nivolumab 480 mg i.v. given on Day 1 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)
Biological: NeoVax · Biological: Nivolumab · Procedure: Research blood draw · Procedure: Leukapheresis for research
Experimental
Cohort D: NeoVax+Ipilimumab+Nivolumab (start with Cycle 3)
* NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase) * Ipilimumab 1 mg/kg i.v. given on Days 1 and 22 of Cycle 1 (priming phase) * Nivolumab 480 mg i.v. given on Day 1 of Cycle 3 and then on Day 1 of each subsequent cycle
Biological: NeoVax · Biological: Nivolumab · Biological: Ipilimumab · Procedure: Research blood draw · Procedure: Leukapheresis for research
Experimental
Cohort E: NeoVax+Ipilimumab+Nivolumab (day 1&15 each cycle)
* NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase) * Ipilimumab 1 mg/kg i.v. given every 6 weeks beginning on Day 1 of Cycle 1 (C1D1, C2D15, C4D1, C5D15, C7D1, C8D15 ...) * Nivolumab 3 mg/kg i.v. given on Days 1 and 15 of each cycle (q2w) beginning on Day 1 of Cycle 1
Biological: NeoVax · Biological: Nivolumab · Biological: Ipilimumab · Procedure: Research blood draw · Procedure: Leukapheresis for research

Interventions

BiologicalNeoVax
At each vaccination time point, patients will receive up to 20 synthetic long peptides co-administered with 1.5 mg of poly-ICLC divided into a maximum of four injections (pools). Each pool (of vaccine + poly IC:LC) will be administered to one of the four limbs (right axilla, left axilla, right inguina, left inguina) by subcutaneous injection.
Also known as: Synthetic long peptides plus poly-ICLC
BiologicalNivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
Also known as: Opdivo
BiologicalIpilimumab
Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)
Also known as: Yervoy
ProcedureResearch blood draw
-Baseline, cycle 2 day 1, cycle 4 day 1, and time of progression or discontinuation of treatment
ProcedureLeukapheresis for research
-Baseline, cycle 4 day 1, and time of progression or discontinuation of treatment

What researchers measure

Primary outcomes

Safety and tolerability of regimen as measured by a <= 33% dose-limiting toxicity (DLT) rate for a given cohort
* The DLT observation period is 60 days after C1D1 for patients enrolled to Cohorts A, C, and D and is 90 days after C1D1 for patients enrolled to Cohorts B and E. * DLT is defined as any grade 3 or greater event that occurs during the DLT observation period that is considered at least possibly related to the study treatment.
Time frame: Up to 90 days after start of treatment
Feasibility of generating a personalized neoantigen peptide vaccine as measured by the ability to identify candidate tumor-specific neoantigens
Time frame: From time of resection to 4 weeks post-radiation therapy (approximately 14 weeks)
Feasibility of generating a personalized neoantigen peptide vaccine as measured by the the ability to manufacture a neoantigen-based synthetic long peptide vaccine
Time frame: From time of resection to 4 weeks post-radiation therapy (approximately 14 weeks)
Feasibility of generating a personalized neoantigen peptide vaccine as measured by the ability to administer the vaccine to a patient at 4 weeks post-completion of radiotherapy
Time frame: From time of resection to 4 weeks post-radiation therapy (approximately 14 weeks)

Secondary outcomes

Immunogenicity of a personalized neoantigen peptide vaccine as measured by the ability to generate a measurable neoantigen-specific T cell response in vaccinated patients
Time frame: Week 4 post-vaccination
Immunogenicity of a personalized neoantigen peptide vaccine as measured by the ability to generate a measurable neoantigen-specific T cell response in vaccinated patients
Time frame: Week 16 post-vaccination
Immunogenicity of a personalized neoantigen peptide vaccine as measured by the number of individual neoantigens per number of neoantigens vaccinated against, with which a measurable T cell-specific response
Time frame: Week 4 post-vaccination
Immunogenicity of a personalized neoantigen peptide vaccine as measured by the number of individual neoantigens per number of neoantigens vaccinated against, with which a measurable T cell-specific response
Time frame: Week 16 post-vaccination
Number of high quality candidate neoantigens present in patients with newly diagnosed glioblastoma
High quality neoantigens will be defined as those that meet criteria for inclusion in a vaccine
Time frame: Up to 2 weeks post sequencing
Progression-free (PFS) survival rate
Time frame: 6 months
Overall survival (OS) rate
Time frame: 12 months

Study locations

1 site

Washington University School of Medicine
Saint Louis, Missouri 63110, United States

References and documents

Study documents

Informed consent form · Jun 18, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

Registry details

Key details

Study ID: NCT03422094
Lead sponsor: Washington University School of Medicine
Collaborators: Bristol-Myers Squibb
Responsible party: Sponsor
First posted: Feb 5, 2018
Start date: Oct 31, 2018
Primary completion: Apr 26, 2020
Completion: Dec 31, 2020
Last update: Oct 27, 2021

Study contacts

Tanner Johanns, M.D., Ph.D.

principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Glioblastoma→

Other studies from this sponsor

Washington University School of Medicine

Start the discussion